v3.26.1
Unaudited Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development expense $ 4,582 $ 12,355
General and administrative expense 4,726 5,259
Total operating expenses 9,308 17,614
Loss from operations (9,308) (17,614)
Other income (expense):    
Interest income 37 400
Gain on warrant liability 2,674 1,880
Gain on PPAs liability 273 0
Other expense (20) 0
Total other income 2,964 2,280
Consolidated net loss and comprehensive loss $ (6,344) $ (15,334)
Net loss per common share, basic $ (4.22) $ (13.16)
Net loss per common share, diluted $ (4.22) $ (13.16)
Weighted-average shares of common stock outstanding, basic 1,501,649 1,164,984
Weighted-average shares of common stock outstanding, diluted 1,501,649 1,164,984